CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Autolus Therapeutics Q3 2026 net loss narrows 30% year over year to $55.09 million

By Public Technologies
  • Autolus Therapeutics’ third-quarter 2026 net loss narrowed 30% year-over-year to $55.1 million.
  • AUCATZYL net product revenue jumped 95% year-over-year to $41.2 million, driven primarily by increasing demand.
  • Gross margin rose to 57% from 55% in the second quarter, supported by manufacturing efficiencies.
  • Initial progressive multiple sclerosis trial data were postponed to October 2027 to allow longer follow-up.
  • Full-year 2026 AUCATZYL net product revenue is now expected to reach or exceed the prior guidance’s $150 million upper end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9873899) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk